tthx1114
Recombinant proteinexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 19, 2020 (NCT04520321)
Timeline
Indications
Mechanism of action
- Acidic fibroblast growth factorSupplementation
FGF1 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05769920 | Phase 1 | Dec 6, 2022 | Trefoil Therapeutics, Inc. |
| NCT04812067 | Phase 2 | Nov 16, 2021 | Trefoil Therapeutics, Inc. |
| NCT04676737 | Phase 2 | Dec 16, 2020 | Trefoil Therapeutics, Inc. |
| NCT04520321 | Phase 1/Phase 2 (Phase 2) | Aug 19, 2020 | Trefoil Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Trefoil Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2020 |
1 organizations
Page 1 / 1